Lowering Prescription Drug Prices: Moving the Ball Forward

The Waxman team will continue to build understanding and technical expertise about the drivers of drug pricing trends and potential policy solutions. It will: 1) inform policymakers and the public about drug pricing problems and developments through a series of Fund blog posts; 2) track and analyze the Food and Drug Administration’s plans for tackling costs as well as steps taken by the Department of Health and Human Services and the Centers for Medicare and Medicaid Services; 3) help the Fund convene an informal discussion group of key stakeholders, such as Patients for Affordable Drugs and the Campaign for Sustainable Rx Pricing, that educate the public and policymakers on drug pricing issues; 4) continue providing technical assistance to Congress, stakeholders, and reporters; and 5) update the Fund’s drug pricing calendar to inform the foundation’s rapid‐response efforts. In addition, former congressman Henry Waxman will participate in a media teleconference hosted by the Fund to discuss salient topics related to drug pricing.